drugset

drugset / Trial / NCT05769478

Effect of Amifampridine on Neuromuscular Transmission in Patients Treated With OnabotulinumtoxinA

NCT05769478 ↗

Phase 1 Completed 21 enrolled Wake Forest University Health Sciences

NaSingle-groupOpen-labelTreatment

Summary

if amifampridine can improve neuromuscular transmission in muscles previously injected with OnabotulinumtoxinA (BTX-A)

Timeline

Start: 2023-09-15
Primary completion: 2024-10-29
Completion: 2024-10-29

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Amifampridine	Small molecule	20 mg	Oral

Indications